EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date...
BAAR, Switzerland, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Samsung Bioepis Co. Ltd, a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European...
The FDA has issued two guidance documents that it says should help make the drug development process more efficient.The first addresses the use of minimal residual disease (MRD) as...
Biogen (NASDAQ:BIIB) Biogen, $BIIB, gapped higher in July and consolidated for 3 weeks before a blow off top and Island reversal. This held in the original gap and has...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Neutral||Sell||Sell||Strong Sell||Buy|
|Technical Indicators||Strong Buy||Strong Sell||Strong Sell||Strong Sell||Strong Buy|
|Summary||Buy||Strong Sell||Strong Sell||Strong Sell||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||1W||Current|
|Engulfing Bearish||1W||2||Sep 30, 2018|
|Three Outside Up||1W||3||Sep 23, 2018|
|Bullish Engulfing||1W||4||Sep 16, 2018|
|PayPal Holdings Inc||77.48||80.44||77.36||-2.61||-3.26%||19.75M||18/10|
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.